Intensive glucose lowering in type 2 diabetes
21 results
1 - 21
Intensive glucose lowering in type 2 diabetes 
Intensive glucose lowering does not benefit patients with type 2 diabetes- Tight glycemic control doesn't decrease ischemic heart disease events (ACCORD)
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients: Cochrane systematic review- Treatment and follow-up in type 2 diabetes
- Long-term follow-up confirms lack of mortality benefit of strict blood sugar control in T2DM
- Intensive control of blood sugar (HbA1c < 7.0%) in DM2 may be harmful (ACCORD)
- Intensive glucose control slightly lowers quality of life scores (ACCORD)
- Bariatric surgery plus intensive medical therapy better than medical therapy alone for diabetes (STAMPEDE)
- Intensive glucose control increases mortality in T2DM (ACCORD)
- Detrimental effect of tight glucose control on CV mortality persists over 9 years
- USPSTF recommends screening for diabetes in hypertensive patients
- Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus
- Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus New
- Glucose targets for preventing diabetic kidney disease and its progression New
- BP target of 120 no better than 140 in T2DM (ACCORD)
- Blood pressure control for diabetic retinopathy: Cochrane systematic review